ILMN
Illumina, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +30.0% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 162 | +8 | 116.88M | $20.55B | +11 | −4 |
| Q1 2026 | 158 | -5 | 113.90M | $14.03B | +5 | −11 |
| Q4 2025 | 162 | 0 | 124.91M | $16.38B | +2 | −1 |
| Q3 2025 | 23 | -1 | 78.13M | $7.41B | +1 | −3 |
| Q2 2025 | 22 | 0 | 71.58M | $6.83B | +1 | −1 |
| Q1 2025 | 19 | 0 | 39.00M | $3.09B | +1 | −1 |
| Q4 2024 | 19 | 0 | 37.37M | $4.99B | +2 | −2 |
| Q3 2024 | 18 | 0 | 20.75M | $2.70B | +1 | −1 |
| Q2 2024 | 18 | n/a | 22.19M | $2.32B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 18.03M | +408.6% | $2.41B | 0.4% | ▲ Add | 3 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 5.79M | n/a | $774.19M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 3.02M | -16.7% | $403.32M | 0.3% | ▼ Trim | 3 | SEC ↗ ×4 |
| 4 | Geode Capital Management ✦ (passive) | 2.73M | +0.2% | $364.67M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | PRIMECAP Management ✦ | 2.46M | -2.4% | $328.17M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 1.71M | -12.1% | $228.71M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 904.86K | -16.5% | $120.92M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 733.92K | -34.1% | $98.07M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 9 | ARK Investment Management ✦ | 686.33K | New | $91.71M | 0.8% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 531.49K | -63.7% | $71.02M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 459.49K | -28.8% | $61.40M | 0.1% | ▼ Trim | 3 | SEC ↗ ×5 |
| 12 | T. Rowe Price ✦ | 108.35K | -3.3% | $14.48M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 13 | Arrowstreet Capital ✦ | 67.52K | New | $9.02M | 0.0% | New | 1 | SEC ↗ |
| 14 | Icahn Capital ✦ | 40.00K | -90.7% | $5.35M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 34.94K | +5.4% | $4.67M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 16 | Gotham Asset Management ✦ | 26.92K | -37.3% | $3.60M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Wellington Management ✦ | 25.30K | -18.2% | $3.38M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 18 | Citadel Advisors ✦ | 8.44K | -46.7% | $1.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | GAMCO Investors ✦ | 1.58K | -18.3% | $211,804 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| ARK Investment Management | $91.71M | 0.8% |
| Arrowstreet Capital | $9.02M | 0.0% |
Exited
| Marshall Wace | $161.68M | was 0.2% |
| Soros Fund Management | $22.82M | was 0.6% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 837 holders, 154.80M shares, $18.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 7.50K sh · $1.63M
Director · 11.35K sh · $2.49M
Director · 100.65K sh · $21.98M
Director · 13.26K sh · $2.87M
Director · 9.96K sh · $2.21M
Director · 6.66K sh · $1.47M
Director · 13.72K sh · $3.01M
Director · 9.72K sh · $2.12M
Director · 14.20K sh · $3.08M
Director · 8.44K sh · $1.82M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology